Logo

VERU

Veru Inc.

VERU

Veru Inc. • NASDAQ
$2.48 ▲ 1.64% (+0.04)
Market Cap $36.34 M
52w High $14.20
52w Low $2.11
Dividend Yield 0%
P/E 0.41
Volume 51.49K
Outstanding Shares 14.65M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $0 $8.031M ▼ $-7.333M ▲ 0% $-0.5 ▲ $-7.546M ▲
Q2-2025 $0 $8.122M ▼ $-7.902M ▲ 0% $-0.54 ▼ $-9.067M ▲
Q1-2025 $0 ▼ $10.249M ▼ $-8.945M ▼ 0% ▲ $-0.32 ▲ $-10.879M ▼
Q4-2024 $6.657M ▲ $10.893M ▼ $-8.531M ▲ -128.154% ▲ $-0.58 ▲ $-7.842M ▲
Q3-2024 $3.954M $12.277M $-10.969M -277.421% $-0.75 $-10.614M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $15.01M ▼ $27.331M ▼ $11.986M ▲ $15.345M ▼
Q2-2025 $20.018M ▼ $32.672M ▼ $11.625M ▼ $21.047M ▼
Q1-2025 $26.607M ▲ $39.829M ▼ $13.202M ▼ $26.627M ▼
Q4-2024 $24.916M ▼ $60.419M ▼ $28.102M ▲ $32.317M ▼
Q3-2024 $29.151M $64.632M $27.011M $37.62M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $-7.333M ▲ $-5.482M ▲ $474.064K ▼ $0 $-5.008M ▲ $-5.482M ▲
Q2-2025 $-7.902M ▲ $-7.736M ▲ $1.148M ▼ $0 ▲ $-6.589M ▼ $-7.736M ▲
Q1-2025 $-8.945M ▼ $-11.333M ▼ $17.245M ▲ $-4.222M ▼ $1.691M ▲ $-11.334M ▼
Q4-2024 $-8.531M ▲ $-4.366M ▲ $131.5K ▲ $0 ▼ $-4.235M ▲ $-4.429M ▲
Q3-2024 $-10.969M $-5.646M $55.37K $3.28K $-5.587M $-5.7M

Revenue by Products

Product Q1-2021Q2-2023Q3-2023Q4-2023
Other Products
Other Products
 $0 ▲$0 ▲$0 ▲$0 ▲
Preboost Segment
Preboost Segment
 $0 ▲$0 ▲$0 ▲$0 ▲

Five-Year Company Overview

Income Statement

Income Statement Veru has effectively become a pre‑revenue biotech. After selling its legacy product business, sales have fallen to a very small level and no longer cover the company’s operating costs. Gross margins on what little revenue remains are fine, but they are irrelevant versus the size of R&D and overhead spending. Profitability has swung from a small profit a few years ago to consistent, meaningful losses more recently, and earnings per share have deteriorated as the company absorbs ongoing development costs without corresponding product income. The income statement now looks like a classic clinical‑stage biotech: low revenue, high R&D intensity, and dependence on future trial success rather than current operations.

Balance Sheet

Balance Sheet The balance sheet has been shrinking. Cash and total assets have come down over the past few years, and shareholders’ equity has been steadily eroded by recurring losses, though it remains positive. Debt appears modest in absolute terms, but relative to a very small asset base, financial flexibility is limited. The divestiture of the prior commercial business brought in cash but also removed a recurring revenue source, so the company is now more reliant on careful cash management, future financings, or partnerships to support its pipeline. Overall, the balance sheet is lean and functional for a development‑stage biotech, but it does not provide a large safety buffer.

Cash Flow

Cash Flow Cash flow shows a company that has been consistently burning cash to fund development. Operating cash flow has been negative every year, with outflows tied primarily to R&D and operating expenses rather than heavy investment in physical assets. There is essentially no capital spending, which is typical for an asset‑light biotech model. This means the main lever on cash burn is the pace of clinical programs and overhead. Without meaningful incoming cash from operations, Veru’s ability to keep funding trials will depend on the remaining cash cushion, access to capital markets, and potential non‑dilutive sources such as partnerships or milestone payments.

Competitive Edge

Competitive Edge Veru’s competitive position rests on a focused but narrow pipeline in large, fast‑growing disease areas. By targeting muscle loss in patients on GLP‑1 weight‑loss drugs and inflammation in cardiovascular disease, the company has aligned itself with two of the highest‑interest themes in healthcare. Enobosarm’s oral formulation and specific focus on preserving muscle make it differentiated versus some injectable competitors, while sabizabulin’s anti‑inflammatory mechanism is distinct from traditional cholesterol‑lowering approaches. However, Veru is small, pre‑commercial, and up against very large, well‑funded pharmaceutical rivals. Its moat is based on patents, unique mechanisms, and clinical data rather than commercial scale, so execution on trials and partnering will be crucial to maintaining relevance.

Innovation and R&D

Innovation and R&D Innovation is the clear centerpiece of Veru’s story. The company has refocused into a pure biopharma model with two main drug candidates and has built a sizable patent estate, including long‑dated protection for its modified‑release enobosarm formulation. The science is positioned around first‑in‑class or highly differentiated mechanisms addressing real unmet needs: preserving muscle quality during GLP‑1‑driven weight loss, and tackling vascular inflammation in heart disease. At the same time, the pipeline is concentrated—most of the value is tied to just these two assets, still in mid‑ to late‑stage development. That concentration creates upside if trials succeed but also heightens risk if data disappoints or timelines slip.

Summary

Veru has transformed from a small product company with modest recurring sales into a development‑stage biotech fully leveraged to its clinical pipeline. Financially, it now looks like a typical high‑risk, high‑uncertainty biotech: minimal revenue, steady losses, negative cash flow, and a slim but still positive equity base. Strategically, the company is pursuing attractive, very large markets with novel, oral drugs and appears to have meaningful intellectual property and a clear development plan. The trade‑off is greater dependence on future clinical and regulatory milestones and on ongoing access to funding. Going forward, the story will be driven far more by trial results, partnership activity, and cash runway management than by traditional earnings metrics or near‑term revenue growth.

NEWS

October 31, 2025 · 8:30 AM UTC

Veru to Present Two Abstracts at ObesityWeek 2025

Read more

October 29, 2025 · 4:01 PM UTC

Veru Announces Proposed Public Offering

Read more

September 23, 2025 · 8:30 AM UTC

Veru Announces Successful FDA Meeting Providing Regulatory Clarity for Enobosarm for Muscle Preservation in Combination with GLP-1 RA for Greater Weight Loss in the Treatment of Obesity

Read more